Veracyte saw the highest growth of 0.49% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.49% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Veracyte‘s patent filings and grants. Buy the databook here.
Veracyte has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 50% grants. The United States(US), and Australia(AU) patent Office are among the top ten patent offices where Veracyte is filings its patents. Among the top granted patent authorities, Veracyte has 50% of its grants in United States(US) and 50% in Australia(AU).
Regeneron Pharmaceuticals could be the strongest competitor for Veracyte
Patents related to rare diseases and healthtech lead Veracyte's portfolio
Veracyte has the highest number of patents in rare diseases followed by, healthtech and machine learning. For rare diseases, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Pneumonia related patents lead Veracyte portfolio followed by hypersensitivity, and lung disease
Veracyte has highest number of patents in pneumonia followed by hypersensitivity, lung disease, bronchiolitis, and sarcoidosis. For pneumonia, nearly 11% of patents were filed and 33% of patents were granted in Q2 2024.
For comprehensive analysis of Veracyte's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.